基本信息
views: 125
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
In the laboratory, his group recently led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, and Nature, and it has received international attention with major clinical implications Dr. Bindra is now translating this work directly into patients, in four phase I/II clinical trials, including an innovative, biomarker-driven trial specifically targeting the Adolescent/Young Adult (AYA) cancer patient population. In addition, he is lead co-PI of a 35-site, NCI-sponsored Phase II trial testing the PARP inhibitor, olaparib, in adult IDH1/2-mutant solid tumors (NCT03212274). As a biotech entrepreneur he recently co-founded Cybrexa Therapeutics, a Series B round-funded company focused on developing an entirely new class of small molecule DNA repair inhibitors, which directly target the tumor microenvironment. Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University in 1998, and both his MD and PhD from the Yale School of Medicine in 2007. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center (MSKCC) in 2012.
Research Interests
Papers共 261 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Prateek Bhardwaj,Ranjini Sundaram, Amro Baassiri, Martin Matthews,Jennifer VanOudenhove,Susan Gueble,Stephanie Halene,Ranjit Bindra
Cancer Researchno. 6_Supplement (2024): 7123-7123
Rifaquat Rahman,Diana D Shi,Zachary J Reitman,Petra Hamerlik,John F de Groot,Daphne A Haas-Kogan, Alan D D'Andrea,Erik P Sulman,Kirk Tanner,Nathalie Y R Agar,Jann N Sarkaria, Christopher L Tinkle,
Neuro-oncology (2024)
Katelyn J. Noronha, Karlie N. Lucas, Sophia J. Zhao, Joseph Edmonds, Sam Friedman, Matthew A. Murray, Samantha Liu,Jiayu Liang,Sateja Paradkar,Hao Zeng,Ranjini K. Sundaram, Josh Spurrier,
Cancer Researchno. 6_Supplement (2024): 3086-3086
Alexander Josowitz,Teresa Lee,Ranjini K. Sundaram,Jinal Pothupitiya, Eric J. Brown,Amrita Sule,Jason Beckta,Yongheng Wang, Joseph Vacca,Oren Gilad,Ranjit S. Bindra,W Mark Saltzman
Cancer Researchno. 6_Supplement (2024): 7117-7117
Eric D Huseman, Anna Lo, Olga Fedorova, James L Elia,Susan E Gueble,Kingson Lin,Ranjini K Sundaram,Joonseok Oh,Jinchan Liu,Fabian Menges,Matthew G Rees,Melissa M Ronan,
Journal of the American Chemical Society (2024)
Sophia J. Zhao, Katelyn J. Noronha, Prateek Bhardwaj, Karlie N. Lucas,Ranjini K. Sundaram, Collin D. Heer, Raffaella Morotti, Josh Spurrier, Mitch Raponi,Ranjit S. Bindra,Juan C. Vasquez
Cancer Researchno. 6_Supplement (2024): 2866-2866
Bruce Ruggeri, Kyle Tarantino,Ranjini K. Sundaram,Kingson Lin,Seth B. Herzon,Joseph Park, Spenser Johnson,Susan Gueble,Ranjit S. Bindra
Cancer Researchno. 7_Supplement (2023): 1132-1132
Science translational medicineno. 720 (2023): eadi1617-eadi1617
Deborah Blythe Doroshow, Wei Wei,Meenakshi Mehrotra, Daniella Sia,Joseph Paul Eder,Ranjit Bindra, Jane Houldsworth,Patricia LoRusso, Zenta Walther
CANCER INVESTIGATIONno. 7 (2023): 646-655
crossref(2023)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn